Results 21 to 30 of about 456,969 (387)

Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization [PDF]

Frontiers in Immunology, 2021
Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses. The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
Dana N. Thornlow, Dana N. Thornlow, Andrew N. Macintyre, Thomas H. Oguin, Amelia B. Karlsson, Erica L. Stover, Heather E. Lynch, Gregory D. Sempowski, Gregory D. Sempowski, Aaron G. Schmidt, Aaron G. Schmidt   +10 more
openaire   +3 more sources

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

New England Journal of Medicine, 2020
Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19 ...
E. Anderson, N. Rouphael, A. Widge, L. Jackson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'dell, S. Schmidt, Kizzmekia S. Corbett, P. Swanson, M. Padilla, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, David R. Martinez, R. Baric, Wendy L. Buchanan, C. Luke, Varun K. Phadke, C. Rostad, J. Ledgerwood, B. Graham, J. Beigel   +36 more
semanticscholar   +1 more source

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity ...
K. Abu Jabal, H. Ben-Amram, K. Beiruti, Yunis Batheesh, Christian Sussan, S. Zarka, M. Edelstein   +6 more
semanticscholar   +1 more source

Immunogenicity of biopharmaceuticals [PDF]

Nephrology Dialysis Transplantation, 2006
The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety of these agents is the potential for immunogenicity.
Huub Schellekens, Michèle Kessler, David Goldsmith   +2 more
openaire   +2 more sources

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Journal of Nanobiotechnology, 2021
Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting ...
Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini, C. Katalani, A. Hajizade, A. Easton, G. Ahmadian   +6 more
semanticscholar   +1 more source

Immunogenicity of sulfatide [PDF]

Immunochemistry, 1977
Abstract The present study deals with the immunogenicity of sulfatide. Despite its acidic character, we succeeded in raising high titer antibodies. The most effective immunization procedure involved repeated intravenous injections of a mixture of sulfatide-lecithin-cholesterol-methylated bovibe serum albumin (1:4:10:10).
B. Zalc, B. Zalc, C. Jacque, C. Jacque, Norman S. Radin, Norman S. Radin, P. Dupouey, P. Dupouey   +7 more
openaire   +4 more sources

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Nature Communications, 2021
The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2.
Jing-hui Tian, N. Patel, Robert E. Haupt, Haixia Zhou, S. Weston, Holly Hammond, James Logue, Alyse D. Portnoff, James Norton, M. Guebre‐Xabier, Bin Zhou, K. Jacobson, Sonia Maciejewski, Rafia Khatoon, Małgorzata Wiśniewska, Will Moffitt, S. Kluepfel-Stahl, Betty Ekechukwu, James F. Papin, S. Boddapati, C. Jason Wong, P. Piedra, M. Frieman, M. Massare, L. Fries, K. Bengtsson, Linda Stertman, L. Ellingsworth, G. Glenn, Gale Smith   +29 more
semanticscholar   +1 more source

Immunogenicity of botulinum toxin [PDF]

Archives of Plastic Surgery, 2022
Botulinum toxin treatment is the most common non-surgical cosmetic treatment. Although there are many available treatments using botulinum toxin, their effects are temporary and repeated injections are required. These frequent injections can trigger an immunological response. In addition, botulinum toxin acts as an antigen in the body; thus, its effect
Syeo Young Wee, Eun Soo Park
openaire   +3 more sources

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

Annals of Internal Medicine, 2021
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine among 133 participants with underlying chronic ...
P. Deepak, Wooseob Kim, Michael A. Paley, Monica M. Yang, A. Carvidi, Emanuel Demissie, Alia A. El-Qunni, Alem Haile, Katherine Huang, Baylee Kinnett, Mariel J. Liebeskind, Zhuoming Liu, L. McMorrow, D. Páez, Niti Pawar, D. Perantie, Rebecca E. Schriefer, Shannon E. Sides, Mahima Thapa, M. Gergely, Suha Abushamma, Sewuese Akuse, Michael K Klebert, Lynne M. Mitchell, D. Nix, J. Graf, K. Taylor, S. Chahin, M. Ciorba, P. Katz, M. Matloubian, Jane A. O’Halloran, R. Presti, Gregory F. Wu, S. Whelan, W. Buchser, L. Gensler, Mary C. Nakamura, A. Ellebedy, A. H. Kim   +39 more
semanticscholar   +1 more source

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Journal of the American Medical Association (JAMA), 2021
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ...
K. Stephenson, Mathieu le Gars, J. Sadoff, A. M. de Groot, Dirk Heerwegh, C. Truyers, C. Atyeo, C. Loos, A. Chandrashekar, K. McMahan, Lisa H. Tostanoski, Jingyou Yu, M. Gebre, C. Jacob-Dolan, Zhenfeng Li, Shivani Patel, Lauren Peter, Jinyan Liu, E. Borducchi, Joseph P. Nkolola, Morgana Souza, C. Tan, Rebecca Zash, B. Julg, R. Nathavitharana, R. Shapiro, Ahmed Abdul Azim, C. Alonso, K. Jaegle, J. Ansel, Diane G Kanjilal, Caitlin J. Guiney, C. Bradshaw, Anna Tyler, Tatenda Makoni, Katherine E. Yanosick, M. Seaman, D. Lauffenburger, G. Alter, F. Struyf, M. Douoguih, J. van Hoof, H. Schuitemaker, D. Barouch   +43 more
semanticscholar   +1 more source